Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

Citations Over TimeTop 10% of 2012 papers

Abstract

PARP inhibitors (PARPi) for the treatment of BRCA1 or BRCA2 deficient tumours are currently the focus of seminal clinical trials exploiting the concept of synthetic lethality. Although clinical resistance to PARPi has been described, the mechanism underlying this has not been elucidated. Here, we investigate tumour material from patients who had developed resistance to the PARPi olaparib, subsequent to showing an initial clinical response. Massively parallel DNA sequencing of treatment-naive and post-olaparib treatment biopsies identified tumour-specific BRCA2 secondary mutations in olaparib-resistant metastases. These secondary mutations restored full-length BRCA2 protein, and most likely cause olaparib resistance by re-establishing BRCA2 function in the tumour cells.

Related Papers

• → Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib(2020)49 cited
• → Synthetic Lethality Triggered by Combining Olaparib with BRCA2–Rad51 Disruptors(2017)40 cited
• → Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors(2016)42 cited
• → Synthetic lethality vs. synthetic viability due to PARP1 and BRCA2 loss(2017)1 cited
• → Biological analysis of the in-vitro effects of homologous recombination inhibition and its use in cancer treatment through synthetic lethality(2021)